News

Givlaari lowers rate of porphyria attacks

Patients with acute hepatic porphyria treated with Givlaari experienced a lower rate of porphyria attacks, according to results of the ENVISION study.Givlaari (givosiran, Alnylam) is a GaINAc-conjugate RNAi therapeutic that targets aminolevulinic acid synase 1 (ALAS1) for the treatment of acute hepatic porphyrias (AHP).“Patients with AHP suffer through debilitating and potentially life-threatening attacks, and for…

News

Q&A: Diversity in GI improves patient outcomes

Diversity in medicine has demonstrated improvements in access to care among undeserved communities and may positively influence health care delivery, patient outcomes and public policy, according to a report in the American Journal of Gastroenterology.The report highlights steps gastroenterology practices can follow to make improvements in diversity and inclusion within the GI field. Healio Gastroenterology…